The new Russian antiviral drug Triazavirin is being tested in China as a cure for the new coronavirus, Russian Deputy Health Minister Sergei Kraeva said on Tuesday. | Coronavirus 2020.
|Triazavirin, coronavirus 2020.|
Coronavirus, 2020 (Russia): The Chinese took Triazavirin for testing," he said. Reported by TASS, February 4.
|Triazavirin structure (Chemical compound), Coronavirus 2020.|
Triazavirin (TZV) is a broad spectrum antiviral drug developed in Russia jointly by Ural Federal University, the Institute of Organic Synthesis of the Russian Academy of Sciences and the Influenza Research Institute of the Russian Health Ministry.
It can be used to treat 15 types of influenza.
In late December 2019, Chinese authorities reported to the World Health Organization (WHO) an outbreak of unknown pneumonia in the city of Wuhan.
Wuhan is a major commercial and industrial metropolis in central China with a population of 11 million people.
The infectious substance was identified as Coronavirus 2019-nCoV, 2020.
Cases of the new coronavirus have also been reported from 24 other countries, including Australia, Canada, India, Thailand, Russia, the United States and Vietnam.
The World Health Organization has declared the new Coronavirus outbreak an international public health emergency.
To date, the number of confirmed cases in China has exceeded 20,400, with more than 420 deaths from the coronavirus. Deaths outside mainland China have also been reported.
Triazavirin is a Russian antiviral drug (Direct-acting antivirals). According to the developers' claims, effective against 15 types of influenza.
It is a synthetic analogue of purine nucleotides (guanine).
Preclinical researches were conducted for more than 20 years. The clinical efficacy of Triazavirin has been declared by the developers as higher than that of Arbidol and Ribavirin.
Scaling up of the technology for the preparation of the drug, bringing the development to the stage of implementation and development of the pharmaceutical form was carried out by Ural Center of Biopharmaceutical Technologies.
The drug is produced at the Medsintez pharmaceutical enterprise in the Urals. Triazavirin appeared on sale in the pharmacy chain at the end of 2014.